Eurasian Forum Slides "The Modern Understanding of Statins from the Intervent...Alexander Kharlamov
These slides were presented at the Eurasian Forum "Medicine, Pharmacy and Public Health" on October 8-9th 2015 in Yekaterinburg, Russia. The report reviews the concerns of the cardiovascular burden exposing critical national risk factors and extremely high mortality rates with the special focus on atherosclerosis, statin drugs and emerging options of interventional cardiology in Russia. The role of blood cholesterol levels in cardiovascular disease (CVD) and the true effect of lipid-lowering therapy are debatable. In particular, whether statins actually decrease cardiac mortality and increase life expectancy is controversial. The statins have gone on to become a multi-billion dollar industry, but the expectation that CVD could be prevented or eliminated by simply reducing cholesterol appears unfounded. More recently, intracoronary imaging modalities have enabled detailed in vivo quantification and characterization of coronary atherosclerotic plaque, serial evaluation of atherosclerotic changes over time, and assessment of vascular responses to effective anti-atherosclerotic medications with a target to achieve atheroregression within Glagov phenomenon. The intensive lipid lowering can halt plaque progression and may even result in regression of coronary atheroma, but results remain very modest and controversial. Statins reduce fibrous tissue and amount of intramural lipids, but with very slight effect on necrotic core and detrimental accelerated calcium deposition. New generations of the lipid-lowering drugs and nanotechnologies amid the revolution in theranostics of atherosclerosis grant us with a hope to achieve atheroregression below 40% Glagovian threshold. Check out my profile (Dr. Alexander Kharlamov) in ResearchGate for more details.
Coronary Calcium and other CVD Risk Biomarkers: From Epidemiology to Comparat...CTSI at UCSF
Presented by Philip Greenland, MD, at UCSF's symposium "The Role of Risk Stratification and Biomarkers in Prevention of Cardiovascular Disease" in Jan 2012.
Eurasian Forum Slides "The Modern Understanding of Statins from the Intervent...Alexander Kharlamov
These slides were presented at the Eurasian Forum "Medicine, Pharmacy and Public Health" on October 8-9th 2015 in Yekaterinburg, Russia. The report reviews the concerns of the cardiovascular burden exposing critical national risk factors and extremely high mortality rates with the special focus on atherosclerosis, statin drugs and emerging options of interventional cardiology in Russia. The role of blood cholesterol levels in cardiovascular disease (CVD) and the true effect of lipid-lowering therapy are debatable. In particular, whether statins actually decrease cardiac mortality and increase life expectancy is controversial. The statins have gone on to become a multi-billion dollar industry, but the expectation that CVD could be prevented or eliminated by simply reducing cholesterol appears unfounded. More recently, intracoronary imaging modalities have enabled detailed in vivo quantification and characterization of coronary atherosclerotic plaque, serial evaluation of atherosclerotic changes over time, and assessment of vascular responses to effective anti-atherosclerotic medications with a target to achieve atheroregression within Glagov phenomenon. The intensive lipid lowering can halt plaque progression and may even result in regression of coronary atheroma, but results remain very modest and controversial. Statins reduce fibrous tissue and amount of intramural lipids, but with very slight effect on necrotic core and detrimental accelerated calcium deposition. New generations of the lipid-lowering drugs and nanotechnologies amid the revolution in theranostics of atherosclerosis grant us with a hope to achieve atheroregression below 40% Glagovian threshold. Check out my profile (Dr. Alexander Kharlamov) in ResearchGate for more details.
Coronary Calcium and other CVD Risk Biomarkers: From Epidemiology to Comparat...CTSI at UCSF
Presented by Philip Greenland, MD, at UCSF's symposium "The Role of Risk Stratification and Biomarkers in Prevention of Cardiovascular Disease" in Jan 2012.
Instability and rupture of atherosclerotic plaques result in acute coronary syndrome.
LDL-C is usually related to ASCVD.
Statin medications are first-line therapy for LDL-C lowering Post ACS.
Rosuvastatin 20mg and 40 mg significantly increase HDL-C levels compared with Atorvastatin 80 mg
Dyslipidemia and CVS by Mohit Soni and Chandan KumarOlgaGoryacheva4
My students Mohit Soni and Chandan Kumar had presented this topic in our 22nd Student Scientific Society Conference in the department of Propaedeutic of Internal Diseases No.2
Instability and rupture of atherosclerotic plaques result in acute coronary syndrome.
LDL-C is usually related to ASCVD.
Statin medications are first-line therapy for LDL-C lowering Post ACS.
Rosuvastatin 20mg and 40 mg significantly increase HDL-C levels compared with Atorvastatin 80 mg
Dyslipidemia and CVS by Mohit Soni and Chandan KumarOlgaGoryacheva4
My students Mohit Soni and Chandan Kumar had presented this topic in our 22nd Student Scientific Society Conference in the department of Propaedeutic of Internal Diseases No.2
diabetes Orientation Talk The dealing with diabetic complications pptxGovindRankawat1
When and how to screen Diabetic Kidney Disease (DKD) And what is the role of Urine Albumin Creatinine Ratio (UACR)
All patients with type 2 diabetes must be screened for diabetic nephropathy at the time of diagnosis.
Patients with type 1 diabetes should be screened five years after diagnosis and at puberty. If the initial test reveals negative result then the test has to be repeated annually for both type 1 and type 2 diabetes.
Early Diabetic kidney disease expressed as Microalbuminuria (if urinary albumin excretion is 30 - 300 mg/24 h.
Random urine samples should be used and the results of albumin measurement in spot collection may be expressed as urinary albumin concentration (mg/dL) or as urinary albumin to creatinine ratio (mg/g or mg/mmol).
This method is often found to be the easiest to carry out in an office setting, generally provides accurate information, and is therefore preferred;
ASA/AHA 2014 guidelines for the Primary Prevention of Stroke
Hypertension and dyslipidemia impact on stroke development and prevention
SPRINT and HOPE-3
There is a Primary Prevent Indication in Diabetes | Mubashar A ChoudryMubashar A Choudry MD
Dr. Mubashar A Choudry, MD, is proud to serve patients at Washington Vascular Specialists, the first outpatient vascular treatment center in the mid-Atlantic region, with locations in Takoma Park, Largo, and Frederick, Maryland. He is a specialist in cardiology medical field.
Diabetes and heart two sides of the same coinSunil Wadhwa
This ppt presented in a CME of doctors in March 2017 discusses-if all Diabetics should be treated aggressively for prevention of coronary artery disease & SHOULD IT BE PRESUMED AS IF THEY ARE ALREADY PATIENTS OF CAD?
This presentation is updated till March 2017
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Cadime algoritmo hipolipemiantes
1. Los algoritmos se basan en las evidencias y recomendaciones de la bibliografía citada, adaptadas a las circunstancias de
nuestro medio.
Algoritmo de tratamiento hipolipemiante en prevención CV
(diciembre, 2015)
CV: cardiovascular; SCA: síndrome coronario agudo; DM: diabetes mellitus; SCORE: Systemic Coronary Risk Evaluation (Recomendado en
Andalucía). (*) Estatinas con relación coste-efectividad más favorable en nuestro medio. Simvastatina: dosis en función de riesgo CV, edad,
tolerabilidad, preferencias del paciente y/o tratamientos concomitantes. SCA: si no se tolera atorvastatina 80 mg/d ↓ dosis a 40 mg/d. (#)
Antecedentes enfermedad CV, obesidad, sedentarismo.
Bibliografía:
- Perk J et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth
Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention
in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;
33(13):1635–701.
- Deanfield J et al. Joint British Societies’ consensus recommentations for the prevention of cardiovascular disease
(JBS3). Heart. 2014; 100(Suppl 2):ii1-ii67.
- NICE. Cardiovascular disease: risk assessment and reduction, including lipid modifification. GC181. 2014.
- Navarro Moya FJ et al. Riesgo Vascular. PAI. 2010.
- Stone NJ et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic
cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task
Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889-934.
- VA/DoD. Clinical practice guideline for the management of dyslipidemia for cardiovascular risk reduction. 2014.
- Los lípidos como factor de riesgo cardiovascular: tratamiento farmacológico. INFAC. 2014; 22(7): 37-43.
- Reiner Z et al. ESC/EAS Guidelines for the management of dyslipemias. The Task Force for the management of
dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
Eur Heart J. 2011; 32(14):1769-818.